Brief: Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)
21/01/2026 12:04
Jan 21 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: DAWNZERA™ (DONIDALORSEN) APPROVED IN THE EUROPEAN UNION FOR HEREDITARY ANGIOEDEMA (HAE) IONIS PHARMACEUTICALS INC - ELIGIBLE FOR MILESTONE PAYMENT OF $15 MILLION AND TIERED ROYALTIES OF UP TO 30% ON NET PRODUCT SALES Source text: ID:nBw1hfhy7a Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors